A new analysis of 25,000 biomarker tests shows that even the most health-conscious people face early warning signs of metabolic and cardiovascular disease.
London, UK, London, February 23, 2026 /EINPresswire.com/ — emeraldThe UK-based preventive healthcare platform has published new analysis of more than 25,000 comprehensive biomarker tests, revealing that early warning signs of long-term illness remain widespread, even among individuals who actively monitor their health.
The analysis examined markers associated with nutritional status, metabolic health, inflammation, and cardiovascular risk. Although Emerald users performed better than the national average on several indicators, the data highlights persistent hidden risks, particularly regarding cholesterol, low-grade inflammation, and early metabolic dysfunction.
The UK continues to face increasing health pressures. Growth in life expectancy has stalled, healthy life expectancy has declined in recent years, and long-term conditions account for a large proportion of NHS spending. However, many of the biological changes that precede chronic disease develop silently in the blood years before diagnosis.
Rather than focusing solely on isolated “problem” markers, Emerald’s analysis investigated how early biological signals emerge and progress over time. This dataset includes longitudinal tests, allowing patterns to be tracked beyond one-time snapshots and providing deeper insight into how individuals move from a state of health to early dysfunction.
Key findings include:
1. More than half of people have elevated cholesterol levels
2. Nearly one in three people had elevated levels of high-sensitivity C-reactive protein (hs-CRP), a marker associated with chronic inflammation.
3. Early signs of blood sugar dysregulation were present even among people of healthy weight
4. Despite high health consciousness, nutritional deficiencies such as vitamin D and iron remain common.
The findings suggest that aggressive people are not immune to underlying biological risks and that traditional symptom-driven medicine may miss early changes.
“Many chronic diseases begin quietly, with no symptoms,” said Dr. Yanis Balanos, General Practitioner and Clinical Director at Emerald. “However, early signs from blood tests, urine tests, and physical measurements can give early warning signs of disease. Tracking these markers over time allows us to identify risks earlier and make more informed health decisions.”
Emerald’s analysis confirms growing support for preventive, data-driven healthcare. Early identification of inflammation, metabolic risks, and nutritional deficiencies may allow changes to be made before disease develops.
As pressures on the NHS continue to increase, early detection and monitoring of risk markers could play an increasingly important role in reducing the long-term disease burden and improving population health.
Read the entire Emerald Health Analysis.
About emerald
Emerald is a UK-based digital health platform focused on preventive healthcare through comprehensive biomarker testing. The platform analyzes blood biomarkers to support early insights into nutritional status, metabolic health, inflammation, and cardiovascular risk.
contact address
Company name: Emerald
Website: https://witherald.com/
Contact name: Alexander Badarian
Contact email address: press@witherald.com
Contact address: 71-75 Shelton Street, Covent Garden, London WC2H9JQ
Toni Coraza
MADX digital
please email here
Legal disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.